FDA agrees 200-patient Phase 3 design for REC-4881 in FAP
Recursion's FDA-agreed 200-patient Phase 3 design for REC-4881 counts 10-mm-plus adenoma removals as events; the FAP trial is planned to start in 2H 2027.
TAG K-8727 · 648 words on the filing

By Olivia Hart
Recursion, the Salt Lake City-based AI drug developer, said on Nov. 18 that the FDA had agreed to the design of a registrational Phase 3 trial of REC-4881, an oral MEK1/2 inhibitor for adults with familial adenomatous polyposis (FAP) who have undergone colectomy or proctocolectomy.
Under the agreed design, the primary endpoint will measure event-free survival from randomization to the first qualifying event. Qualifying events include:
- Removal of an adenoma measuring 10 mm or larger in either the upper or lower gastrointestinal tract.
- Meeting prespecified criteria for FAP-related surgery.
- Developing high-grade dysplasia or cancer.
- Death.
Recursion plans to start the study in the second half of 2027.
Without surgery to remove the colon, the lifetime risk of colorectal cancer in people with classic FAP approaches 100%. Mutations in the APC gene cause the syndrome. After colectomy, polyps can still form in the remaining rectum or ileal pouch and in the upper gastrointestinal tract.
Patients face lifelong endoscopic surveillance, repeated polyp removal and, in some cases, further major surgery. FAP has no FDA-approved drug therapy.
“Adenomas 10 millimeters and larger are associated with increased cancer risk and are nowadays routinely removed in patients with FAP. However, removal carries risks of bleeding and perforation, alongside the burden of repeated procedures and intensive surveillance,” said Evelien Dekker, a professor of gastrointestinal oncology at Amsterdam University Medical Center.
What does this change for FAP development?
The FDA agreement fixes the event definition for a registrational test. Recursion expects to enroll about 200 adults in a randomized, double-blind, placebo-controlled trial with a prespecified interim analysis.
The study will test a 4 mg dose, and Recursion will use ongoing TUPELO data to set the dosing schedule. Key secondary endpoints are progression on the modified Spigelman scale, which grades duodenal polyposis severity, and total polyp burden.
The practical change is the endpoint: Phase 3 will measure clinical events tied to adenomas at or above 10 mm, not only short-window changes in pooled polyp counts. The agreement does not resolve whether REC-4881 can produce that effect.
TUPELO supplies the signal, with a key caveat
Data presented Nov. 2 from the ongoing Phase 1b/2 TUPELO trial showed:
- A median 47% reduction in total polyp burden among 15 patients after 12 weeks of REC-4881 at 4 mg once daily.
- Lower polyp burden than baseline in 11 of 13 evaluable patients, or 85%, 12 weeks after treatment stopped.
- Grade 3 treatment-related adverse events in four of 26 safety-evaluated patients, or 15%, with no grade 4 or 5 treatment-related events.
- Fewer polyps above 5 mm in six of eight patients with lesions above that size at baseline, after 12 weeks.
TUPELO grouped all polyps larger than 5 mm together, so the data do not reveal how many adenomas met the Phase 3 threshold of 10 mm or larger. That limits direct translation from the early efficacy signal to the registrational endpoint.
A Takeda asset identified through phenotypic screening
Takeda first developed REC-4881 as TAK-733, and Recursion licensed it in 2020. Recursion says it used phenotypic screening with its AI models to identify the drug’s potential in FAP.
After narrowing TUPELO enrollment to patients aged 55 and older while it evaluated adverse events, Recursion reopened enrollment to adults aged 18 and older, R&D World reported in July.
A second Phase 3 entrant is already enrolling
Biodexa Pharmaceuticals is already running a registrational Phase 3 trial of eRapa, an oral formulation of rapamycin, in patients with FAP. The company said Nov. 9 that it had enrolled 112 of a planned 168 participants.
For Recursion, the work now shifts from endpoint design to execution: use TUPELO to set dosing, start the 200-patient study in the second half of 2027, and determine whether adenoma reduction translates into fewer qualifying events.
via recursion.com (Original)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- V-5532
- P-9899
- C-4460
- C-7994
- C-6506